Beam Therapeutics Inc (BEAM) — Capital Reinvestment Ratio

Latest as of December 2023: 0.03x

Beam Therapeutics Inc (BEAM) has a Capital Reinvestment Ratio of 0.03x as of December 2023, meaning it reinvests 0% of its operating cash flow ($135.07 Million) in capital expenditures ($3.59 Million). See Beam Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

0.03x
Capex / Operating Cash Flow

Operating Cash Flow

$135.07 Million
USD

Capital Expenditures

$3.59 Million
USD

Data as of

Dec 2023
Most recent filing

Beam Therapeutics Inc Capital Reinvestment Ratio (2022–2022)

This chart tracks Beam Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods.

Annual Capital Reinvestment Ratio for Beam Therapeutics Inc (2022–2022)

Year-by-year Capital Reinvestment Ratio for Beam Therapeutics Inc from 2022 to 2022. For live market cap and broader valuation context, see market value of Beam Therapeutics Inc.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2022 2.17x $22.53 Million $48.95 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow